Venrock Adviser, LLC — 13F Holdings & Portfolio
CIK 1615982 · latest 13F-HR filed 2026-08-14
Venrock Adviser, LLC manages $3.30B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are APGE (34.18%), ORKA (11.97%), ERAS (9.94%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions and exited 4; 18 existing positions rose in reported value and 6 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- APOGEE THERAPEUTICS INC$412.4M +57.7%
- ORUKA THERAPEUTICS INC$191.3M +94.0%
- SPYRE THERAPEUTICS INC$79.2M +42.6%
- ERASCA INC$62.7M +23.7%
- JADE BIOSCIENCES INC$26.3M +58.1%
Top Trims
- ENLIVEN THERAPEUTICS INC-$41.0M -60.5%
- CYTOMX THERAPEUTICS INC-$28.2M -60.2%
- VIRIDIAN THERAPEUTICS INC-$16.1M -21.2%
- COGENT BIOSCIENCES INC-$13.4M -17.4%
- ORIC PHARMACEUTICALS INC-$7.9M -14.5%
New Positions
- ACHIEVE LIFE SCIENCE INC$18.0M
- PARABILIS MEDICINES INC$17.1M
- RESEARCH ALLIANCE CORP III$3.2M
- INMED PHARMACEUTICALS INC$50.7K
Exited Positions
- KALVISTA PHARMACEUTICALS INC$130.3M
- ENGENE HOLDINGS INC$32.5M
- TENAX THERAPEUTICS INC$26.8M
- SEPTERNA INC$12.2M
Venrock Adviser, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $1.13B | 34.18% | 8,493,321 | SH |
| 2 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $394.8M | 11.97% | 4,148,428 | SH |
| 3 | ERASCA INC | ERAS | 29479A108 | $327.8M | 9.94% | 17,891,812 | SH |
| 4 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $265.0M | 8.04% | 2,985,448 | SH |
| 5 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $115.0M | 3.49% | 1,180,000 | SH |
| 6 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $101.6M | 3.08% | 10,346,926 | SH |
| 7 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $93.7M | 2.84% | 3,603,595 | SH |
| 8 | SAVARA INC | SVRA | 805111101 | $90.8M | 2.75% | 14,745,943 | SH |
| 9 | JADE BIOSCIENCES INC | JBIO | 008064206 | $71.6M | 2.17% | 3,220,364 | SH |
| 10 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $63.6M | 1.93% | 1,642,166 | SH |
| 11 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $59.8M | 1.81% | 3,257,917 | SH |
| 12 | VOR BIOPHARMA INC | VOR | 929033207 | $56.0M | 1.70% | 3,041,719 | SH |
| 13 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $48.3M | 1.46% | 2,173,913 | SH |
| 14 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $47.8M | 1.45% | 1,602,034 | SH |
| 15 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $47.4M | 1.44% | 6,844,305 | SH |
| 16 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $46.8M | 1.42% | 4,319,765 | SH |
| 17 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $38.4M | 1.16% | 2,133,576 | SH |
| 18 | ZURA BIO LTD | ZURA | G9TY5A101 | $38.0M | 1.15% | 6,434,990 | SH |
| 19 | ADLAI NORTYE LTD | ANL | 00704R109 | $36.9M | 1.12% | 3,212,731 | SH |
| 20 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $26.7M | 0.81% | 526,331 | SH |
| 21 | CYBIN INC | HELP | 23256X407 | $25.5M | 0.77% | 3,851,654 | SH |
| 22 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $25.1M | 0.76% | 1,379,965 | SH |
| 23 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $21.3M | 0.65% | 8,695,652 | SH |
| 24 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $19.8M | 0.60% | 2,043,596 | SH |
| 25 | CYTOMX THERAPEUTICS INC | CTMX | 23284F105 | $18.7M | 0.57% | 4,982,124 | SH |
| 26 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $18.0M | 0.54% | 2,751,032 | SH |
| 27 | PARABILIS MEDICINES INC | PBLS | 698955101 | $17.1M | 0.52% | 625,000 | SH |
| 28 | SURROZEN INC | SRZN | 86889P208 | $16.4M | 0.50% | 632,931 | SH |
| 29 | KORRO BIO INC | KRRO | 500946108 | $13.3M | 0.40% | 1,009,500 | SH |
| 30 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $13.2M | 0.40% | 500,000 | SH |
| 31 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $9.0M | 0.27% | 1,934,253 | SH |
| 32 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $3.2M | 0.10% | 300,000 | SH |
| 33 | INMED PHARMACEUTICALS INC | INM | 457637700 | $50.7K | 0.00% | 32,685 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $3.30B | 33 | 0001615982-26-000015 |
| 2026-03-31 | 2026-05-15 | $2.68B | 33 | 0001615982-26-000011 |
| 2025-12-31 | 2026-02-17 | $2.02B | 27 | 0001615982-26-000005 |
| 2025-09-30 | 2025-11-14 | $1.78B | 33 | 0001615982-25-000006 |
23RD FLOOR
NEW YORK, NY 10018